VYNE Q4 2023 Earnings Report
Key Takeaways
VYNE Therapeutics reported its financial results for the fourth quarter and year ended December 31, 2023. The company had cash, cash equivalents, restricted cash and marketable securities of $93.3 million as of December 31, 2023, which it believes will be sufficient to fund operations through the end of 2025.
Entered 2024 with positive momentum, highlighted by clinical proof-of-concept data for VYN201 and a successful financing.
On track to initiate a Phase 2b trial in nonsegmental vitiligo next quarter for VYN201.
Expect to submit supplemental nonclinical information to the FDA in the coming weeks for VYN202.
Assuming FDA clearance, expect to commence Phase 1a SAD/MAD trial next quarter for VYN202.
VYNE
VYNE
Forward Guidance
VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of December 31, 2023 will be sufficient to fund its operations through the end of 2025.